Hammerhead ribozymes as therapeutic agents for bladder cancer.
Hammerhead ribozymes have been investigated extensively as therapeutic agents against cancer. Aberrant or overexpression of genes related to tumorigenicity or cancer growth might be the appropriate targets for ribozyme strategies. Ribozyme-mediated gene therapy should be applied to those diseases that have no successful conventional therapy such as advanced or treatment-resistant bladder cancer. Many genetic alterations have been identified in bladder cancer related to both tumorigenesis and disease progression. Mutated H-ras, fos, and erb-B2 genes have been chosen as targets for ribozymes in previous studies, and antitumor efficacy has been demonstrated by reversion of the malignant phenotypes and by inhibition of tumor growth both in vitro and in vivo. The efficiency of various delivery systems has also been evaluated. An overview of ribozyme strategies, especially for therapeutic applications against bladder cancer, is described here.
Irie
A
A
Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. akira_irie@pop07.odn.ne.jp
Kashani-Sabet
M
M
Scanlon
K J
KJ
Uchida
T
T
Baba
S
S
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D004195:Disease Models, Animal; D018734:Genes, erbB-2; D011905:Genes, ras; D015316:Genetic Therapy; D006801:Humans; D009690:Nucleic Acid Conformation; D016337:RNA, Catalytic / Q000737:chemistry / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000628:therapy*
D016337:RNA, Catalytic; D012333:RNA, Messenger